Bio-Rad Laboratories, Inc. (BIO) Stock Analysis

Company Overview

The market values Bio-Rad Laboratories, Inc. (BIO) at $9.43B. The company sits in the Healthcare sector, in the Medical Devices industry. The company reports 7,450 employees.

Over the past 52 weeks the price has ranged from $236.73 to $396.23. The most recent close on file for BIO is $360.50, dated October 21, 2026. That is +$6.00 (+1.69%) against the previous close. The latest close sits 52.28% above that 52-week low.

Financial Health

In fiscal 2025, Bio-Rad Laboratories, Inc. reported revenue of $2.58B. That is +0.65% against the prior fiscal year, when revenue was $2.57B. The same year closed with net income of $759.90M. Profit margin runs at 8.59%. That is 23.4 percentage points above the Medical Devices median of −14.78%. Earnings per share on a trailing basis come to 7.89.

Across the 4 fiscal years on file, revenue moves from $2.80B in 2022 to $2.58B in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The trailing P/E ratio stands at 44.72. That is 65.14% above the Medical Devices median of 27.08. The forward P/E on file is 36.2. The PEG ratio, which sets the P/E against expected earnings growth, reads 4.01. Measured against sales, the shares trade at 3.64 times revenue. On price-to-sales that is 44.02% above the Medical Devices median of 2.53. The medians here are taken across 145 Medical Devices companies that report the metric.

Over the trailing twelve months the total return is +8.82%. Across 10 years the annualized return works out at +8.26%. The reported beta is 1.07. Annualized volatility over the trailing 10 years is 34.38%.

Growth & Income

No dividend is on file for BIO.

Across the complete calendar years on file, 2019 returned +59.34% and 2022 returned −44.35%. Of the 9 complete calendar years on file, 5 finished higher. 2026 is still running; the total return is +18.98% year to date.